KCNA3 and head and neck squamous cell carcinoma: Short-term treatment of HNSCC T cells with atezolizumab (1 and 10 μg/ml for 6 h) increased KCa3.1 function, while Kv1.3 function was increased only at the higher concentration (Figures 3A,B).